Dr Joseph Mitchell Jabbour, MD | |
22071 Sam Fred Rd, Middleburg, VA 20117-3201 | |
(540) 687-6607 | |
(540) 687-6607 |
Full Name | Dr Joseph Mitchell Jabbour |
---|---|
Gender | Male |
Speciality | Plastic Surgery |
Location | 22071 Sam Fred Rd, Middleburg, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1235483348 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | 0101054565 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr Joseph Mitchell Jabbour, MD 22071 Sam Fred Rd, Middleburg, VA 20117-3201 Ph: (540) 687-6607 | Dr Joseph Mitchell Jabbour, MD 22071 Sam Fred Rd, Middleburg, VA 20117-3201 Ph: (540) 687-6607 |
News Archive
St. Luke's Episcopal Hospital (St. Luke's) joins John Goss, M.D., in celebrating his milestone as he recently performed his 1,000th liver transplantation procedure. The largest liver transplant program in Houston's world-renowned Texas Medical Center, St. Luke's performs approximately 75 liver transplants annually. Additionally, St. Luke's liver transplant survival rate is the highest in the nation, with a one-year adult patient survival rate of 96.5 percent compared to the national expected survival rate of 89.38 percent.
A recent discovery by Van Andel Research Institute (VARI) scientists enables the prediction of patient sensitivity to proposed drug therapies for glioblastoma - the most common and most aggressive malignant brain tumor in humans.
Innovative product development and technology consultancy firm Cambridge Consultants has collaborated with Clinigen Group to create a new way of identifying fresh market applications for drugs nearing the end of their product lifecycle.
Pfizer Inc. announced that top-line results of a double-blind, Phase 3 study evaluating pregabalin controlled-release (CR) formulation in patients with fibromyalgia indicate that pregabalin CR had a statistically significant positive effect compared to placebo in the primary endpoint, time to loss of therapeutic response (LTR).
› Verified 9 days ago